drugset / Trial / NCT01547299
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Phase 2
Completed
52 enrolled
Pfizer
Astellas Pharma Inc · collabMedivation LLC, a wholly owned subsidiary of Pfizer Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
Timeline
- Start
- 2012-03-31
- Primary completion
- 2013-11-30
- Completion
- 2013-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Background | Dutasteride | Small molecule | 0.5 mg | Oral |
| Background | Leuprolide | Other / unclassified | 22.5 mg | Intramuscular |